Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results: Loss Per Share of $0.13

Poniard Pharmaceuticals, Inc. PARD, a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the third quarter ended September 30, 2010. The Company reported a net loss of $6.4 million ($0.13 diluted loss per share on a loss applicable to common shares of $6.5 million) for the quarter ended September 30, 2010, compared with a net loss of $9.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $10.0 million) for the quarter ended September 30, 2009. For the first nine months of 2010, the net loss was $24.9 million ($0.55 diluted loss per share on a loss applicable to common shares of $25.6 million), compared to a net loss of $32.5 million ($0.95 diluted loss per share on a loss applicable to common shares of $32.9 million) for the same period in 2009.